LEGENDS OF SUPPLEMENTARY FIGURES

Suppl Figure 1. (A) Expression of cytotolytic molecules on transduced T cells showing no difference between GFP^{+} and TRAIL^{+}T cells. **(B, C)** B6→CBF1+LB27.4 allo-BMT is described in Figure 1. **(B)** Necropsy was performed on animals found dead during survival monitoring and the cause of death tabulated. **(C)** Weekly GVHD clinical scores. (*** $p<0.001$).

Suppl Figure 2. Recipients of BALB/c→BALB/c syn-BMT were adoptively transferred with $5x10^{6}$/recipient B6 allo-preT cells. Spleen and thymus were harvested on **(A)** Day 14 and **(B)** Day 28 and the number of preT-derived cells calculated. **(C)** Percentage frequency of preT-derived splenic CD4 and CD8 T cells at day 28 were determined.

Suppl Figure 3. (A, B) B6→CBF1 allo-BMT is described in Figure 1A, B, C, D. Weekly weight changes as an indicator of GVHD was monitored. **(C)**. B6→CBF1 allo-BMT were left either untreated or adoptively transferred with donor GFP^{+} and TRAIL^{+}T cells, and subsequently inoculated with LCMV. Splenocytes from the inoculated recipients were harvested and cocultured with vero cells to determine PFU/mg (*$p<0.05$, ***$p<0.001$).

Suppl Figure 4. PBMCs from CLL patients – CLL-1 and CLL-2 – were analyzed by flow cytometry. **(A)** DAPI^{+}excluded live events are studied for expression of

CD19 and CD5, showing 56% and 60% putative CLL cells. **(B)** DAPI^{+}excluded live events are studied for expression of DR4 and DR5.

A



B

Tumor dose: $2x10^5$/rcpt. T cell dose: $0.5x10^6$/rcpt

		Tumor	GVHD	Alive
□	B6 BMT	0	0	10
■	B6 BMT+LB27.4	10	0	0
◇	+GFP$^+$T cells	2	4	4
◆	+TRAIL$^+$T cells	0	0	10

Tumor dose: $1x10^5$/rcpt. T cell dose: $1x10^6$/rcpt

		Tumor	GVHD	Alive
■	B6 BMT+LB27.4	9	0	1
◇	+GFP$^+$T cells	1	9	0
◆	+TRAIL$^+$T cells	0	0	10

C



suppl Figure 1


A
Day 14
Thymocytesx10^6
25
20
15
10
5
Splenocytesx10^5
10
8
6
4
2
B
Day 28
Thymocytesx10^5
2.5
2.0
1.5
1.0
0.5
Splenocytesx10^6
5
4
3
2
1
B6 preT cells + BALB/c → BALB/c
GFP+ preT cell-derived
TRAIL+ preT cell-derived
C
% Frequency
80
60
40
20
CD4
CD8





suppl Figure 3



suppl Figure 4